Press Releases Keyword Search Year None202120202019201820172016201520142013 06/09/21 Avadel Presents New Clinical Data from Pivotal Phase 3 REST-ON Trial Supporting Clinical Benefit of FT218 in Patients with Narcolepsy at SLEEP 2021 Data show improvement in excessive daytime sleepiness for both narcolepsy subtypes and with and with... 06/03/21 Avadel to Present New Efficacy and Safety Data from Pivotal Phase 3 REST-ON Trial of FT218 at SLEEP 2021 DUBLIN, Ireland , June 03, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com... 06/02/21 Avadel Pharmaceuticals Expands Leadership Team with Three Strategic Hires Bolsters team with addition of established biopharma industry leaders in advance of anticipated regu... 05/25/21 Avadel Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference DUBLIN, Ireland , May 25, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a comp... 05/10/21 Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2021 Financial Results Announced FDA acceptance of NDA for once-nightly FT218 and an October 15, 2021 target action PDUFA d... 04/29/21 Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2021 Financial Results on May 10th DUBLIN, Ireland , April 29, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co... 04/17/21 Avadel Presents New Data from its Pivotal REST-ON Phase 3 Trial of FT218, once-nightly sodium oxybate, at the 2021 American Academy of Neurology Annual Meeting Secondary endpoint data for once-nightly FT218 further supports previously announced topline data de... 04/08/21 Avadel to Present New Data from its Pivotal REST-ON Phase 3 Study of FT218 at the American Academy of Neurology Annual Meeting 2021 DUBLIN, Ireland , April 08, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co... 03/18/21 Avadel Pharmaceuticals to Participate in a Fireside Chat at Stifel’s Third Annual CNS Day on March 31st DUBLIN, Ireland , March 18, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co... 03/09/21 Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results New Drug Application (NDA) for once-nightly FT218 to treat excessive daytime sleepiness and cataplex... 03/04/21 Avadel Pharmaceuticals and the American Academy of Sleep Medicine Foundation Announce an Exclusive Collaboration on the 2021 Young Investigators Research Forum Avadel to support AASM Foundation scholarships and training for early career sleep researchers DUBLI... 03/02/21 Avadel Pharmaceuticals Announces Publication of Once-Nightly FT218 Pharmacokinetic Studies DUBLIN, Ireland , March 02, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co... 03/01/21 Avadel Pharmaceuticals Announces FDA Acceptance of New Drug Application for FT218 in Adults with Narcolepsy for the Treatment of Excessive Daytime Sleepiness and Cataplexy FT218 assigned PDUFA target action date of October 15, 2021 DUBLIN, Ireland , March 01, 2021 (GLOBE ... 02/25/21 Avadel Pharmaceuticals to Participate in Fireside Chats at Upcoming March 2021 Investor Conferences DUBLIN, Ireland , Feb. 25, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com... 02/23/21 Avadel Pharmaceuticals to Provide a Company Update and Report Fourth Quarter and Full Year 2020 Financial Results, on March 9th DUBLIN, Ireland , Feb. 23, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com... 02/17/21 Avadel Pharmaceuticals Appoints Richard Kim as Chief Commercial Officer to Lead the Commercial Launch of Once-Nightly FT218 DUBLIN, Ireland , Feb. 17, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com... 02/10/21 Avadel Pharmaceuticals to Participate in a Fireside Chat at the 10th Annual SVB Leerink Global Healthcare Conference DUBLIN, Ireland , Feb. 10, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
06/09/21 Avadel Presents New Clinical Data from Pivotal Phase 3 REST-ON Trial Supporting Clinical Benefit of FT218 in Patients with Narcolepsy at SLEEP 2021 Data show improvement in excessive daytime sleepiness for both narcolepsy subtypes and with and with...
06/03/21 Avadel to Present New Efficacy and Safety Data from Pivotal Phase 3 REST-ON Trial of FT218 at SLEEP 2021 DUBLIN, Ireland , June 03, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
06/02/21 Avadel Pharmaceuticals Expands Leadership Team with Three Strategic Hires Bolsters team with addition of established biopharma industry leaders in advance of anticipated regu...
05/25/21 Avadel Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference DUBLIN, Ireland , May 25, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a comp...
05/10/21 Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2021 Financial Results Announced FDA acceptance of NDA for once-nightly FT218 and an October 15, 2021 target action PDUFA d...
04/29/21 Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2021 Financial Results on May 10th DUBLIN, Ireland , April 29, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co...
04/17/21 Avadel Presents New Data from its Pivotal REST-ON Phase 3 Trial of FT218, once-nightly sodium oxybate, at the 2021 American Academy of Neurology Annual Meeting Secondary endpoint data for once-nightly FT218 further supports previously announced topline data de...
04/08/21 Avadel to Present New Data from its Pivotal REST-ON Phase 3 Study of FT218 at the American Academy of Neurology Annual Meeting 2021 DUBLIN, Ireland , April 08, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co...
03/18/21 Avadel Pharmaceuticals to Participate in a Fireside Chat at Stifel’s Third Annual CNS Day on March 31st DUBLIN, Ireland , March 18, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co...
03/09/21 Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results New Drug Application (NDA) for once-nightly FT218 to treat excessive daytime sleepiness and cataplex...
03/04/21 Avadel Pharmaceuticals and the American Academy of Sleep Medicine Foundation Announce an Exclusive Collaboration on the 2021 Young Investigators Research Forum Avadel to support AASM Foundation scholarships and training for early career sleep researchers DUBLI...
03/02/21 Avadel Pharmaceuticals Announces Publication of Once-Nightly FT218 Pharmacokinetic Studies DUBLIN, Ireland , March 02, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co...
03/01/21 Avadel Pharmaceuticals Announces FDA Acceptance of New Drug Application for FT218 in Adults with Narcolepsy for the Treatment of Excessive Daytime Sleepiness and Cataplexy FT218 assigned PDUFA target action date of October 15, 2021 DUBLIN, Ireland , March 01, 2021 (GLOBE ...
02/25/21 Avadel Pharmaceuticals to Participate in Fireside Chats at Upcoming March 2021 Investor Conferences DUBLIN, Ireland , Feb. 25, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
02/23/21 Avadel Pharmaceuticals to Provide a Company Update and Report Fourth Quarter and Full Year 2020 Financial Results, on March 9th DUBLIN, Ireland , Feb. 23, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
02/17/21 Avadel Pharmaceuticals Appoints Richard Kim as Chief Commercial Officer to Lead the Commercial Launch of Once-Nightly FT218 DUBLIN, Ireland , Feb. 17, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
02/10/21 Avadel Pharmaceuticals to Participate in a Fireside Chat at the 10th Annual SVB Leerink Global Healthcare Conference DUBLIN, Ireland , Feb. 10, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
